Palvella Therapeutics (NASDAQ:PVLA) Announces Quarterly Earnings Results, Misses Estimates By $0.35 EPS

Palvella Therapeutics (NASDAQ:PVLA) issued its quarterly earnings results on Tuesday. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35), Zacks reports.

Here are the key takeaways from Palvella Therapeutics’ conference call:

• QTORIN rapamycin’s NDA remains on track for completion in the second half of 2026, with potential FDA approval in the first half of 2027. FDA granted rolling review, supported by the product’s Fast Track and Breakthrough Therapy designations.
• The company highlighted strong phase III SELVA results in microcystic lymphatic malformations, including improvement in 95% of patients at week 24 and a favorable safety profile. Palvella plans to pursue a broad label that includes pediatric patients and is targeting a potential first-line therapy.
• Palvella is expanding its commercial infrastructure ahead of a potential launch, including increasing its planned sales force to approximately 40 representatives, building medical affairs and patient-support teams, and engaging more than 200 of 400 targeted clinics.
• The pipeline continues to advance, with a phase III study in cutaneous venous malformations expected to begin in the fourth quarter of 2026, a phase II angiokeratoma study already underway, and a phase II DSAP study expected to start in the fourth quarter. The company expects additional QTORIN program announcements later this year.
• FDA did not grant Breakthrough Therapy Designation for the cutaneous venous malformation program based on the initial 12-week data package. Palvella plans to resubmit using 24-week efficacy results and qualitative patient data, while increased commercial and medical investments raised expected 2026 cash expenses to approximately $85 million-$95 million.

Palvella Therapeutics Stock Performance

PVLA stock traded up $4.31 during midday trading on Tuesday, reaching $145.09. 40,415 shares of the company traded hands, compared to its average volume of 277,049. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -34.75 and a beta of -0.17. Palvella Therapeutics has a 52-week low of $36.93 and a 52-week high of $161.38. The business has a 50 day moving average of $130.73 and a 200-day moving average of $118.68.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Stephens reiterated an “overweight” rating and set a $220.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Wall Street Zen cut shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Chardan Capital upgraded Palvella Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $270.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, July 22nd. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Palvella Therapeutics has an average rating of “Buy” and an average price target of $207.36.

Insider Buying and Selling at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total transaction of $476,360.46. Following the sale, the chief operating officer owned 2,154 shares in the company, valued at approximately $238,512.42. This represents a 66.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 17.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its position in shares of Palvella Therapeutics by 116.4% during the fourth quarter. Russell Investments Group Ltd. now owns 1,229 shares of the company’s stock worth $129,000 after purchasing an additional 661 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of Palvella Therapeutics in the fourth quarter worth about $238,000. Two Sigma Investments LP bought a new position in shares of Palvella Therapeutics in the third quarter worth about $256,000. Franklin Resources Inc. purchased a new position in Palvella Therapeutics in the 3rd quarter worth about $292,000. Finally, Intech Investment Management LLC purchased a new position in Palvella Therapeutics in the 3rd quarter worth about $259,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.